The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.

The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.

Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

The invention relates to antibacterial compounds of formula I

##STR00001##

wherein R.sup.1a, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5, U.sup.l, U.sup.2, U.sup.3, U.sup.4, V.sup.1, V.sup.2, V.sup.3, V.sup.4, X and Q and n are as defined in the specification. It further relates pharmaceutical compositions containing these compounds and the uses of these compounds in the manufacture of medicaments for the treatment of bacterial infections. These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram-positive and Gram-negative aerobic and anaerobic bacteria.

An organic light-emitting material and the manufacturing method thereof, and an organic light-emitting device are disclosed. The organic light-emitting material includes a benzophenanthrene derivative, which has good planarity and strong visible π-π* absorption ability and has a high quantum yield of blue light-emitting capability as well. Therefore, a benzophenanthrene derivative having a large π-conjugated system has high-efficiency electron transporting properties, and its high electron-withdrawing group increases electron mobility rate and effectively improve the light-emitting efficiency of the organic light emitting device.

An organic light-emitting material and the manufacturing method thereof, and an organic light-emitting device are disclosed. The organic light-emitting material includes a benzophenanthrene derivative, which has good planarity and strong visible π-π* absorption ability and has a high quantum yield of blue light-emitting capability as well. Therefore, a benzophenanthrene derivative having a large π-conjugated system has high-efficiency electron transporting properties, and its high electron-withdrawing group increases electron mobility rate and effectively improve the light-emitting efficiency of the organic light emitting device.

The present invention relates to a method for the synthesis of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (i.e. iriniotecan), comprising: (a) preparing 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptotecin; and (b) selectively ethylating the compound of step (a) at the 7-position, thus resulting in the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin. The present invention is further directed to the use of 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (i.e. 7-des-ethyl-irinotecan) as intermediate in a method for the synthesis of irinotecan as described.